EcoDrugPlus

Dopamine Receptor D1b

Ensembl ID : ENSLBEG00000024953
Gene Symbol: DRD1B
1 Cross references
198 Possible Orthologues:

Dopamine Receptor D2

Ensembl ID : ENSLBEG00000019605
Gene Symbol: DRD2
3 Cross references
208 Possible Orthologues:

Dopamine Receptor D3

Ensembl ID : ENSLBEG00000018697
Gene Symbol: DRD3
3 Cross references
202 Possible Orthologues:

Dopamine Receptor D4

Ensembl ID : ENSLBEG00000004894
Gene Symbol: DRD4
3 Cross references
165 Possible Orthologues:

Dopamine Receptor D5

Ensembl ID : ENSLBEG00000027579
Gene Symbol: DRD5
2 Cross references
147 Possible Orthologues:

Dual Specificity Mitogen-Activated Protein Kinase Kinase 2

Ensembl ID : ENSLBEG00000018179
Gene Symbol: LOC109982751
3 Cross references
212 Possible Orthologues:

Dual Specificity Mitogen-Activated Protein Kinase Kinase 2-Like

Ensembl ID : ENSLBEG00000000771
Gene Symbol: LOC109984063
3 Cross references
200 Possible Orthologues:

Ectonucleotide Pyrophosphatase/phosphodiesterase 2

Ensembl ID : ENSLBEG00000026306
Gene Symbol: ENPP2
3 Cross references
226 Possible Orthologues:

Egl Nine Homolog 2-Like

Ensembl ID : ENSLBEG00000026189
Gene Symbol: LOC109988015
2 Cross references
191 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSLBEG00000020108
Gene Symbol: EGLN1
1 Cross references
151 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSLBEG00000006588
Gene Symbol: EGLN1
3 Cross references
216 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 3

Ensembl ID : ENSLBEG00000004818
Gene Symbol: EGLN3
3 Cross references
198 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).